CD274 and small cell lung carcinoma: The results of our study were consistent with recently reported outcomes (20), indicating the satisfactory performance of neoadjuvant PD-(L)1 blockade-based immunotherapy combined with chemotherapy in optimizing the outcomes of patients with LS-SCLC.